Literature DB >> 250503

Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases.

R W Dhurandhar, K Nademanee, A M Goldman.   

Abstract

Three patients developed episodes of ventricular tachycardia and/or flutter-fibrillation while receiving disopyramide (Norpace). Syncope was the presenting complaint in all of them. The arrhythmias did not recur after disopyramide was discontinued. The Q-T interval was markedly prolonged in all three patients. One patient developed syncope associated with both quinidine and Norpace therapy. It is postulated that disopyramide, like quinidine, may provoke ventricular flutter-fibrillation in sensitive patients by similar mechanisms.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 250503

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  5 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 2.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 3.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

Review 4.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

5.  Aggravation of ventricular arrhythmia. A drug-induced complication.

Authors:  P J Podrid
Journal:  Drugs       Date:  1985       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.